Smarter Oncology, Faster Access: How Anna Forsythe and Oncoscope-AI Are Reengineering Cancer Care
This article was originally published in Entrepreneur on 25 September 2025. In oncology, a cascade of new trials, approvals, and guideline updates has become the norm. Yet the systems meant to translate that progress into care haven’t kept pace. Clinicians and product teams are inundated with data, but rarely is it organized to support fast, defensible decisions at the point of need. The result is often delays in care and lost time for patients. Recognizing this disconnect, Anna Forsythe, a pharmacist, health economist, and founder of Oncoscope-AI, built a solution. Motivated by personal experience, including friends and colleagues who received care that lagged behind the evidence, she fused clinical insight with commercial acumen to create a platform that supports clinical decision-making and strategic evidence planning. Her timing couldn’t be more critical. Today’s environment is split between regulatory acceleration and payer caution. Regulators increasingly offer accelerated pathways for medicines addressing unmet needs. Meanwhile, national payers demand deeply contextualized evidence before granting public reimbursement. This tension, compounded by external reference pricing and strategic launch sequencing, has led to uneven access across countries. Oncoscope-AI was designed to operate precisely in this gap between clinical urgency and regulatory rigor. For physicians, it can compress hours of literature review into seconds. By entering stage, genetic markers, and prior therapies, clinicians receive a human-reviewed, guideline-aligned summary that surfaces survival outcomes, progression metrics, toxicity data, and approval status. Each data point is linked directly to primary studies and relevant guidelines for transparency and traceability. This clinical precision is matched by commercial depth. Market access teams can define Population, Intervention, Comparator, Outcome (PICO) criteria, retrieve relevant studies, map drug availability across jurisdictions, and run simulations to model market impact and reimbursement risk. These capabilities are increasingly vital amid European Health Technology Assessment(HTA) reform, where Joint Clinical Assessments (JCAs) will standardize evidence evaluation across Member States. For qualifying products, developers must now submit evidence simultaneously to both the European Medicines Agency and the HTA secretariat, raising the bar for dossier preparation. Anticipating this evolution, Oncoscope-AI’s roadmap now integrates European regulatory guidance, reimbursement decisions, and localized guideline text. It also provides exportable, auditable evidence tables to support dossier preparation. Its simulation engine runs on a continuously updated, expert-validated dataset. This helps ensure that market models reflect current trial outcomes and regulatory activity, not static literature snapshots. Forsythe shares her observations of industry behavior. She acknowledges why companies sequence launches and manage pricing. “These are rational responses to fiscal realities and international price governance. But I believe technology can mitigate the inequities those strategies often produce,” she says. Oncoscope-AI blends trained AI with human curation. The AI scans registries, preprints, journals, and filings to surface signals at scale. Domain experts validate relevance, extract numerical endpoints, and provide regulatory context. “Physicians don’t need more reading material,” Forsythe says. “They need the timely, relevant information that is tailored to the patient in front of them.” For pharmaceutical teams, this translates into strategic preparedness. By identifying emerging comparators, simulating comparative effectiveness, and organizing evidence into auditable PICO-driven exports, companies can build stronger, timelier market access dossiers and anticipate reimbursement questions before they escalate. Industry analysts and consultancies have urged similar readiness strategies as the JCA takes effect. Users are already seeing results. Oncoscope-AI’s simulation outputs pinpoint country-level evidence gaps and shorten dossier preparation. Exportable, PICO-aligned tables and country trackers allow teams to respond the moment a guideline or reimbursement decision changes, without restarting literature reviews from scratch. It’s worth emphasizing that Forsythe frames equitable access not as a moral debate, but as a design challenge. She argues that system-level fixes, rather than focusing solely on industry behavior, will expand reach. Oncoscope-AI positions itself as a bridge between AI innovation and regulatory rigor at a time when scientific velocity often outpaces legacy workflows. The platform isn’t built for shortcuts. It’s built for readiness: an auditable, clinician-trusted channel from discovery to delivery. For Forsythe, the mission is both professional and ethical. She says, “If we want better outcomes in cancer care, we don’t need more information; we need smarter information.”
The Market Access Podcast: Will AI and Living Reviews Define the Next Era of Health Care Market Access?
Oncoscope-AI Founder & CEO Anna Forsythe was recently on the Market Access Podcast with Dr. Stefan Walzer to discuss how Living Systematic Literature Reviews (Living SLRs) are redefining evidence generation in oncology and beyond – highlighting the power of real-time updates, advanced automation, and the essential role of human insight. Traditional SLRs are static snapshots, while Living SLRs are real-time, dynamic, and AI-powered—delivering continuously updated insights crucial for life-or-death decisions and payer evaluations. Join this discussion as they explore the myth of AI chatbots as true decision support tools, the need for actionable data over summaries, and the future of evidence synthesis, clinical decision-making, and smarter market access. Listen on Spotify: Listen on YouTube: Listen on PocketCasts:
OncoDaily Interview: Could Oncoscope-AI Save Clinicians Hours – and Spare Patients Side Effects?
It’s good to talk about our 𝘄𝗵𝘆 sometimes. That’s why we appreciate Emma Ter-Azaryan’s interview so much. Not just for her insightful questions, but for giving us an opportunity to publicly reflect on 𝘄𝗵𝗮𝘁 𝗢𝗻𝗰𝗼𝘀𝗰𝗼𝗽𝗲-𝗔𝗜 𝗺𝗲𝗮𝗻𝘀 𝘁𝗼 𝘂𝘀. In this interview with OncoDaily, Oncoscope-AI Founder & CEO Anna Forsythe shares what drives her personally, an example of an oncologist using the tool and the impact it had, and the frustration of seeing people we love treated with chemotherapy because their doctors weren’t aware of updates in the guidelines and the research behind them. You can watch the full interview “Could Oncoscope-AI Save Clinicians Hours – and Spare Patients Side Effects?” here: From OncoDaily: In this episode of OncoDaily TV, host Emma Ter-Azaryan speaks with Anna Forsythe, CEO & Founder of Oncoscope-AI, to unpack how clinicians can cut through oncology’s data overload—FDA labels, guidelines, congress abstracts, and papers—and get to the right evidence in just a few clicks. What you’ll learn: ✅ What OncoScope AI is (in simple terms): a clinician-friendly “Expedia for evidence” that pulls from major medical databases, guidelines, regulatory updates, and congress outputs—cross-linked in one place.✅ Essential vs. Edge: two workflows—patient-first decision support vs. deep-dive topic exploration (e.g., ADCs in lung cancer, mutation-specific updates).✅ Power features: clickable disease maps, filter by congress (ASCO, World Lung, etc.), tumor-board prep, and one-click prior-auth reports with citations.✅ Real-world impact: how a brand-new FDA approval surfaced that week and helped a patient access a better-tolerated therapy sooner.”
The Healthy Enterprise Podcast: AI’s Role in Modern Oncology – A New Era of Evidence-Based Cancer Care
Our very own Founder & CEO Anna Forsythe was recently on The Healthy Enterprise podcast to talk about Oncoscope-AI and how our practice-changing platform delivers real-time treatment insights, clinical guidelines, and research to support oncologists in an ever-evolving cancer landscape. Watch on YouTube: Listen on Spotify: Listen on Pocket Casts: From The Healthy Enterprise Podcast: In this episode of The Healthy Enterprise, Anna Forsythe, founder and CEO of Oncoscope-AI, shares her journey from manually processing oncology data to creating an AI-powered platform that delivers real-time treatment insights, clinical guidelines, and research to support oncologists in an ever-evolving cancer landscape. She discusses the importance of reliable evidence in decision-making, the positive response from physicians using the free platform, and the role of systematic data reviews in building trust and efficiency. Beyond the technology, Anna reflects on her entrepreneurial path, the challenges and opportunities of leading in healthcare, and the importance of cultivating talent, mission-driven culture, and visionary leadership. The conversation concludes with her insights on business models, community impact, and the future of AI in advancing cancer care. Chapters: 00:00 Introduction to Oncoscope-AI and Anna Forsythe03:04 The Need for Real-Time Oncology Data05:59 Transitioning from Manual to Automated Data Processing09:11 The Role of AI in Oncology12:13 Feedback and Response from Healthcare Professionals14:45 Data Sources and Systematic Reviews in Oncology18:02 Future Developments and Expanding Services21:53 AI in Research: Balancing Trust and Efficiency25:52 Business Model and Revenue Streams29:44 Personal Journey and Altruism in Business32:56 Challenges and Opportunities in Healthcare35:34 Leadership and Team Dynamics39:29 Visionary Leadership and Future Aspirations Guest Information: Takeaways: Keywords: Oncology, AI, healthcare, data processing, clinical guidelines, cancer treatment, healthcare technology, real-time data, systematic reviews, healthcare professionals, AI, healthcare, business model, cancer treatment, research, leadership, altruism, revenue streams, technology, innovation Enjoy this clip from the episode:
Oncoscope-AI Launches Edge for Leaders Shaping the Next Standard of Cancer Care
This press release was originally published to EINPresswire on 28 August 2025. NEW YORK, NY, UNITED STATES, August 28, 2025 /EINPresswire.com/ — Oncoscope-AI, a pioneer in real-time oncology evidence solutions, today announced the launch of Oncoscope Edge, a premium decision-support platform designed for oncology leaders and decision-makers who demand comprehensive, flexible, and actionable insights. In today’s fast-moving oncology landscape, specialists face an overwhelming volume of data—from thousands of new clinical trials to rapidly evolving guidelines and regulatory updates. Oncoscope Edge empowers oncologists, fellows-in-training, researchers, and educators with advanced tools to find, filter, and synthesize the evidence that matters most. “Oncoscope Edge is built for the leaders shaping the next standard of care,” said Anna Forsythe, PharmD, MBA, Founder and CEO of Oncoscope-AI. “Whether you are preparing for a congress talk, conducting a scientific project, guiding a tumor board, or training the next generation of oncologists, Edge delivers clarity from complexity—instantly.” Advanced Features of Oncoscope Edge include: With these capabilities, Oncoscope Edge goes beyond surface-level searches, available now in Oncology-AI’s Essential tool, to deliver deeper, customizable searches and user-generated reports—enabling oncology leaders to stay ahead in a field where evidence evolves daily. About Oncoscope-AI Oncoscope-AI is the first real-time oncology information platform integrating treatment data, guidelines, peer-reviewed publications, and regulatory approvals. By combining AI-powered systematic literature reviews with expert human validation, Oncoscope ensures that oncology decision-making is grounded in the most current and reliable evidence. Sign up for a free license key (verified health care professionals only) or to receive a demo.
In the AI Era, Are Doctors Still at the Cutting Edge of Medicine? Oncoscope-AI Founder Anna Forsythe Asks
This article was originally published in Success Magazine. Artificial intelligence (AI) has revolutionized industries, from finance and logistics to advertising and agriculture. It has offered new efficiencies, insights and capabilities that were seemingly unimaginable just a few decades ago. Healthcare is no exception. In oncology, especially, where the volume of emerging research and the complexity of personalized treatments are accelerating, intelligent tools have become integral. Oncoscope-AI, an advanced oncology intelligence platform, was created to respond to this need. The catalyst behind the founding of the company was a profound question: How can AI help doctors keep up with and apply the flood of cancer breakthroughs to improve real-world patient care? The company has made answering that question its mission. Refining the approach to cancer treatment Anna Forsythe, founder of Oncoscope-AI, believes the cancer landscape today is vastly different from what it was 10 years ago. This is particularly evident in breast and lung cancer, two of the most commonly diagnosed cancers worldwide. “Before, a diagnosis of breast cancer meant a standard treatment regimen for nearly all patients. Individual biological differences didn’t matter. But our understanding has evolved,” Forsythe explains. Indeed, what was called “breast cancer” is now understood as multiple subtypes. Each has its own biological behavior, prognosis and treatment response. Similarly, lung cancer has splintered into a web of genetically and immunologically distinct conditions. The era of the one-size-fits-all approach, dominated by blanket chemotherapy, surgery and radiation, is fading. A more refined model of cancer treatment has emerged in its place. Forsythe states that today’s oncology is driven by two approaches. One is immunotherapy, which amplifies the body’s immune response to fight the disease from within. The other is targeted therapy, which focuses on specific biomarkers or genetic mutations within the tumor itself. They’re usually used in tandem with the goal of turning terminal-stage cancers into manageable, chronic conditions. Consider the arrival of CDK4/6 inhibitors palbociclib, ribociclib and abemaciclib and how they changed the landscape for breast cancer treatment. According to research based on trials, CDK4/6 inhibitors are considered revolutionary in breast cancer treatment and have played a key role in slowing progression. Progression-free survival, or how long a patient can live without the cancer worsening, has become the new benchmark of success. New challenges for physicians This progress introduces a new kind of pressure, however. “With every new biomarker discovered, every new targeted therapy or immunotherapy approved, the challenge for physicians multiplies,” Forsythe states. “How can any oncologist stay up to date with thousands of new studies, frequent regulatory updates and a deluge of clinical data?” At a single oncology conference, countless new abstracts may be released in just one cancer type. The expectation is that doctors will somehow process all of this while continuing to see patients, manage treatments and fulfill legal requirements for ongoing medical education. In theory, continuous medical education (CME) should help doctors stay current. In practice, it’s difficult for health professionals to retain all the information. Enter Oncoscope-AI Oncoscope-AI has emerged to empower healthcare professionals. Forsythe, a pharmacist, health economist and former pharmaceutical executive, designed it to bridge the divide between cutting-edge research and practical clinical application. The platform scans thousands of oncology publications using proprietary AI, filters them through an evidence-based framework and presents only the most clinically actionable insights. According to Oncoscope-AI, these findings are reviewed and contextualized by a human research team before being published in the system. The impact of Oncoscope-AI is best felt in patient stories. A friend Forsythe met while traveling was diagnosed with metastatic breast cancer. She had undergone traditional chemotherapy and surgery that left her physically and emotionally drained. “She was then prescribed one of the breakthrough CDK4/6 inhibitors. Her life changed. She regained energy, joy, and time,” Forsythe shares. However, when her cancer began to progress again, her oncologist defaulted to standard chemotherapy, believing there were no more options. There were. However, the doctor didn’t know. Forsythe sent her friend research summaries and articles through Oncoscope-AI, which she later shared with her doctor. She was then prescribed a new-generation therapy. “She’s thriving now,” says Forsythe. “She just returned from a trip to France and is booking another.” Aiming to help health professionals and patients thrive This story raises a question. How many more patients are out there who could live longer, better lives if only their doctors had access to the right information at the right time? “The problem is not the doctors. It’s the data overload,” Forsythe emphasizes. “The solution isn’t replacing physicians with AI, but equipping them with AI tools that distill noise into knowledge and confusion into clarity.” Oncoscope-AI is striving to do just that. It’s working to help oncologists across the globe turn the latest science into tangible outcomes for patients in the exam room, not months later when guidelines catch up. This article is for informational purposes only and does not substitute for professional medical advice. If you are seeking medical advice, diagnosis or treatment, please consult a medical professional or healthcare provider.
Oncology AI & Trust: Humans First
Recorded live on 01 August 2025, a timely and thought-provoking discussion on the evolving role of AI in oncology—and why human judgment must remain at the center of every decision. As AI tools become increasingly integrated into cancer care, questions of trust, transparency, and responsibility are more important than ever. In this expert panel, we’ll explore where AI adds the most value, where caution is needed, and how we keep humans firmly in the driver’s seat. Speakers: Moderated by:
New Features Now Live in v1.2!
Oncoscope-AI continues to improve and evolve. Our latest update makes finding the clinical evidence you need – even if you aren’t sure what that is yet – even faster and easier.